Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Year in Review
  • Published:

Prostate cancer in 2011

Hitting old targets better and identifying new targets

Nature Reviews Clinical Oncology volume 9, pages 70–72 (2012)Cite this article

Subjects

Options to treat late-stage castration-resistant prostate cancer continued to increase in 2011, as three agents with different mechanisms of action prolonged life and a fourth reduced the morbidity of skeletal metastases. These outcomes contrasted with the heightened controversy generated by the recommendation against PSA screening and other early detection strategies.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Clinical states model of prostate cancer progression and systemic therapies shown to improve survival for castrate disease.

References

  1. de Bono, J. S. et al. Abiraterone and increased survival in metastatic prostate cancer. N. Engl. J. Med. 364, 1995–2005 (2011).

    Article  CAS  Google Scholar 

  2. Parker, C. et al. Overall survival benefit of radium-223 chloride (Alpharadin™) in the treatment of patients with symptomatic bone metastases in castration-resistant prostate cancer (CRPC): a phase III randomized trial (ALSYMPCA) [abstract]. Eur. J. Cancer 47, a7003 (2011).

    Article  Google Scholar 

  3. Medivation. Medivation and Astellas announce positive survival data from interim analysis of phase 3 AFFIRM trial of MDV3100 in men with advanced prostate cancer [online], (2011).

  4. Fizazi, K. et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet 377, 813–822 (2011).

    Article  CAS  Google Scholar 

  5. Yu, E. Y. et al. Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancer. Clin. Cancer Res. 15, 7421–7428 (2009).

    Article  CAS  Google Scholar 

  6. Hussain, M. et al. Cabozantinib (XL184) in metastatic castration-resistant prostate cancer (mCRPC): Results from a phase II randomized discontinuation trial [abstract]. J. Clin. Oncol. 29 (Suppl.), a4516 (2011).

    Article  Google Scholar 

  7. Hugosson, J. et al. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol. 11, 725–732 (2010).

    Article  Google Scholar 

  8. Schröder, F. H. et al. Screening and prostate-cancer mortality in a randomized European study. N. Engl. J. Med. 360, 1320–1328 (2009).

    Article  Google Scholar 

  9. Andriole, G. L. et al. Mortality results from a randomized prostate-cancer screening trial. N. Engl. J. Med. 360, 1310–1319 (2009).

    Article  CAS  Google Scholar 

  10. Chou, R. et al. Screening for prostate cancer: a review of the evidence for the U. S. Preventive Services Task Force. Ann. Intern. Med. 155, 762–771 (2011).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Human Oncology and Pathogenesis Program and Department of Medicine, Memorial Sloan–Kettering Cancer Center, 1275 York Avenue, New York, 10065, NY, USA

    Yu Chen & Howard I. Scher

Authors
  1. Yu Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Howard I. Scher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Howard I. Scher.

Ethics declarations

Competing interests

H. I. Scher acts a as a consultant for Amgen, Dendreon, Exelixis, Medivation, Ortho Biotech Oncology Research & Development and Sanofi-Aventis. He also receives grant support from Medivation and Ortho Biotech Oncology Research & Development. Y. Chen declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Chen, Y., Scher, H. Hitting old targets better and identifying new targets. Nat Rev Clin Oncol 9, 70–72 (2012). https://doi.org/10.1038/nrclinonc.2011.213

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2011.213

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer